Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY) Sees Large Drop in Short Interest

Key Points

• Otsuka Holdings Co., Ltd. experienced a **73.8% drop** in short interest from July 15th to July 31st, falling from **34,000 to 8,900 shares**.
• The company's stock is currently trading at **$26.70**, with a market capitalization of **$28.68 billion** and a price-to-earnings ratio of **0.18**.
• Otsuka Holdings is involved in various sectors including **pharmaceuticals**, **nutraceuticals**, and **medical devices**, focusing on areas like psychiatry, oncology, and ophthalmology.

Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - ) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 8,900 shares, adropof73.8% from the July 15th total of 34,000 shares. Based on an average daily volume of 106,700 shares, the days-to-cover ratio is presently 0.1 days. Approximately0.0% of the company's stock are sold short. Approximately0.0% of the company's stock are sold short. Based on an average daily volume of 106,700 shares, the days-to-cover ratio is presently 0.1 days.

Otsuka Stock Performance

OTCMKTS OTSKY opened at $26.70 on Friday. The firm has a 50 day simple moving average of $24.22 and a 200-day simple moving average of $24.63. Otsuka has a one year low of $21.64 and a one year high of $32.41. The firm has a market cap of $28.68 billion and a price-to-earnings ratio of 0.18.

Otsuka Company Profile

Otsuka Holdings Co, Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.